AGIOS PHARMACEUTICALS, INC. (AGIO) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, AGIOS PHARMACEUTICALS, INC.'s filing signal continuing negative.

Agios Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and delivering innovative medicines for rare diseases, with a particular emphasis on hematology. The company's lead product, mitapivat, is approved in the U.S. as AQVESMETM for anemia in adults with alpha- or beta-thalassemia and as PYRUKYND(R) for hemolytic anemia in adults with pyruvate kinase (PK) deficiency. Agios is also advancing tebapivat for lower-risk myelodysplastic syndromes and sickle cell disease, AG-181 for phenylketonuria, and AG-236 for polycythemia vera. The company's strategy centers on its expertise in cellular metabolism and classical hematology to build a sustainable rare disease business.

Revenue is primarily driven by sales of PYRUKYND(R) in the United States and internationally through distribution agreements. The company anticipates future revenue from AQVESMETM following its U.S. launch.